A phase 1b, multi-centre, parallel group, single blind study to evaluate the safety, tolerability and immunogenicity of a recombinant plague vaccine (rF1 and rV antigens) [Yersinia pestis vaccine] in healthy subjects

Trial Profile

A phase 1b, multi-centre, parallel group, single blind study to evaluate the safety, tolerability and immunogenicity of a recombinant plague vaccine (rF1 and rV antigens) [Yersinia pestis vaccine] in healthy subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 14 Sep 2008

At a glance

  • Drugs Yersinia pestis vaccine (Primary)
  • Indications Plague
  • Focus Adverse reactions
  • Sponsors PharmAthene
  • Most Recent Events

    • 14 Sep 2008 Primary outcome identified as safety as reported by ClinicalTrials.gov
    • 14 Sep 2008 Actual patient number (123) added as reported by ClinicalTrials.gov.
    • 10 Sep 2008 PharmAthene reported as trial sponsor by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top